Evidence map›Paper›PMID 25934767›Full record

ArticleHaematologica2015

Deficiency in mouse hyaluronidase 2: a new mechanism of chronic thrombotic microangiopathy.

Cécile Onclinx, Sophie Dogne, Laurence Jadin, Fabienne Andris, Christian Grandfils, François Jouret, François Mullier, Bruno Flamion

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Hyaluronan: An Architect and Integrator for Cancer and Neural Diseases.International journal of molecular sciences · 2025
    Review
  2. Review
  3. Review
  4. Article
  5. Hyaluronan in inflammatory bowel disease: Cross-linking inflammation and coagulation.Matrix biology : journal of the International Society for Matrix Biology · 2019
    Review
  6. Review
  7. Article
  8. Article
  9. The role of hyaluronan in the pathobiology and treatment of respiratory disease.American journal of physiology. Lung cellular and molecular physiology · 2016
    Review
  10. HYAL-2-WWOX-SMAD4 Signaling in Cell Death and Anticancer Response.Frontiers in cell and developmental biology · 2016
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Cécile OnclinxMolecular Physiology Research Unit, NARILIS, University of Namur, Belgium.
Sophie DogneMolecular Physiology Research Unit, NARILIS, University of Namur, Belgium.
Laurence JadinMolecular Physiology Research Unit, NARILIS, University of Namur, Belgium.
Fabienne AndrisLaboratoire d'Immunobiologie, Institut de Biologie et de Médecine Moléculaire, Université Libre de Bruxelles, Belgium.
Christian GrandfilsInterfacultary Research Centre of Biomaterials (CEIB), University of Liège, Belgium.
François JouretGroupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA), Cardiovascular Sciences, University of Liège, Quartier Hôpital, Avenue Hippocrate, Belgium.
François MullierHematology Laboratory, Namur Thrombosis and Hemostasis Center, CHU Dinant Godinne UCL Namur, Belgium.
Bruno FlamionMolecular Physiology Research Unit, NARILIS, University of Namur, Belgium bruno.flamion@unamur.be.
University of Namur · BEUniversity of Liège · BECHU Dinant Godinne UCL Namur · BEUniversité Libre de Bruxelles · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyaluronan is a major component of the extracellular matrix and glycocalyx. Its main somatic degrading enzymes are hyaluronidases 1 and 2, neither of which is active in the bloodstream. We generated hyaluronidase 2-deficient mice. These animals suffer from chronic, mild anemia and thrombocytopenia, in parallel with a 10-fold increase in plasma hyaluronan concentration. In this study we explored the mechanism of these hematologic anomalies. The decreased erythrocyte and platelet counts were attributed to peripheral consumption. The erythrocyte half-life was reduced from 25 to 8 days without signs of premature aging. Hyaluronidase 2-deficient platelets were functional. Major intrinsic defects in erythrocyte membrane or stability, as well as detrimental effects of high hyaluronan levels on erythrocytes, were ruled out in vitro. Normal erythrocytes transfused into hyaluronidase 2-deficient mice were quickly destroyed but neither splenectomy nor anti-C5 administration prevented chronic hemolysis. Schistocytes were present in blood smears from hyaluronidase 2-deficient mice at a level of 1% to 6%, while virtually absent in control mice. Hyaluronidase 2-deficient mice had increased markers of endothelial damage and microvascular fibrin deposition, without renal failure, accumulation of ultra-large multimers of von Willebrand factor, deficiency of A Disintegrin And Metalloproteinase with ThromboSpondin type 1 motifs, member 13 (ADAMTS13), or hypertension. There was no sign of structural damage in hepatic or splenic sinusoids, or in any other microvessels. We conclude that hyaluronidase 2 deficiency induces chronic thrombotic microangiopathy with hemolytic anemia in mice. The link between this uncommon condition and hyaluronidase 2 remains to be explored in humans.

Indexed as

ADAMTS13 ProteinAnemia, MacrocyticAnimalsBlood ViscosityBone Marrow TransplantationCell SurvivalCellular SenescenceDisease Models, AnimalErythrocyte IndicesErythrocytesErythrocytes, AbnormalErythrocyte TransfusionGPI-Linked ProteinsHyaluronic AcidHyaluronoglucosaminidaseKidneyADAMTS13 ProteinADAMTS13 protein, mouseGPI-Linked ProteinsHyal2 protein, mouseHyaluronic AcidHyaluronoglucosaminidaseMetalloendopeptidases

Identifiers

PMID25934767
PMCPMC5004417
OpenAlexW2118523629

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.